Eisai Co., Ltd. (TYO:4523)
Japan · Delayed Price · Currency is JPY | Market Cap | 1.22T -1.4% |
| Revenue (ttm) | 804.39B +6.8% |
| Net Income | 49.37B +20.5% |
| EPS | 175.06 +22.2% |
| Shares Out | 281.89M |
| PE Ratio | 24.63 |
| Forward PE | 24.40 |
| Dividend | 160.00 (3.71%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 1,725,000 |
| Average Volume | 1,385,045 |
| Open | 4,293.00 |
| Previous Close | 4,270.00 |
| Day's Range | 4,271.00 - 4,332.00 |
| 52-Week Range | 3,463.00 - 5,349.00 |
| Beta | -0.26 |
| RSI | 34.75 |
| Earnings Date | Feb 9, 2026 |
About Eisai
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. It also offers prescription medicines. In addition, the company focuses on neurology and oncology and therapeutic areas. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan. [Read more]
Full Company ProfileFinancial Performance
In fiscal year 2025, Eisai's revenue was 789.40 billion, an increase of 6.42% compared to the previous year's 741.75 billion. Earnings were 46.43 billion, an increase of 9.49%.
Financial StatementsNews
FDA Accepts To Priority Review Eisai And Biogen's LEQEMBI SBLA For Early Alzheimer's Disease
(RTTNews) - Eisai Co., Ltd, (4523.T, ESALY.PK, ESALF.PK), a Japanese commercial-stage biotechnology firm and Biogen Inc. (BIIB) said the U.S. Food and Drug Administration (FDA) has accepted for priori...
FDA Grants Priority Review To Eisai And Biogen's SBLA For LEQEMBI Subcutaneous Autoinjector
(RTTNews) - Eisai Co., Ltd. (ESALY, ESALF, 4523.T) and Biogen Inc. (BIIB) announced that the U.S. Food and Drug Administration has accepted for review Eisai's Supplemental Biologics License Applicatio...
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA acti...
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA acti...
LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Eisai Co Ltd (4523)
LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Eisai Co Ltd (4523)
Nuvation Bio (NUVB) Expands Global Reach with Eisai Collaboration
Nuvation Bio (NUVB) Expands Global Reach with Eisai Collaboration
China’s new drug insurance: lifeline for patients or squeeze on big pharmaceutical firms?
Mainland China’s 17 million Alzheimer’s patients can, for the first time, pay less out of pocket for a costly drug touted as “historic” and “the beginning of the end” for the memory-robbing disease af...
Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions Transcript
Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions December 9, 2025 1:30 AM ESTCompany ParticipantsAya...
Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions - Slideshow
Eisai And Biogen Report Long-Term Benefits Of LEQEMBI In Early Alzheimer's Disease
(RTTNews) - Eisai Co., Ltd. and Biogen Inc. announced new findings on the continued and expanding benefit of LEQEMBI (lecanemab-irmb) maintenance treatment in early Alzheimer's disease at the 18th Cli...
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
TOKYO and CAMBRIDGE, Mass., Dec. 3, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
Eisai : Etalanetug Demonstrates Reduction Of EMTBR-tau243 In Phase Ib/II Alzheimer's Study
(RTTNews) - Eisai Co., Ltd. announced new data on its anti-tau antibody etalanetug at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. Etalanetug is designed to bind to the microtubu...
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Etalanetug demonstrated reduction of eMTBR-tau243, a novel CSF and plasma biomarker that specifically reflects tau tangle pathology, in Phase I b /II study TOKYO , Dec. 1, 2025 /PRNewswire/ -- Eisai C...
Biogen, Eisai File In Japan To Make Leqembi A Weekly At-Home Alzheimer's Shot
Biogen Inc. ‘s (NASDAQ: BIIB) partner Eisai Co., Ltd , on Friday filed a new drug application for Leqembi (lecanemab) seeking approval for a subcutaneous formulation (SC-AI) as a new route of adminis...
Eisai Announces Filing Of New Drug Application For Leqembi In Japan
(RTTNews) - BioArctic AB's (BIOA-B.ST) partner Eisai (4523.T) announced that they have filed a new drug application for Leqembi or lecanemab for a subcutaneous formulation as a new route of administra...
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
TOKYO and CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ: BIIB , Corporate headquarters: Cambridge, Massac...
Eisai to Present Data on Lecanemab Continued Treatment, Subcutaneous Initiation Dosing, and Real-World Experience at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline explore long-term treatment with lecanemab and estimated time savings over 10 years, safety and potential benefits of subcutaneous...
Q2 2026 Eisai Co Ltd Earnings Presentation Transcript
Q2 2026 Eisai Co Ltd Earnings Presentation Transcript
Eisai Co., Ltd. 2026 Q2 - Results - Earnings Call Presentation
Eisai Co., Ltd. (ESAIY) Q2 2026 Earnings Call Transcript
Eisai reports H2 results
Eisai H1 Profit Rises
(RTTNews) - Eisai Co. reported that its first half profit attributable to owners of the parent was 24.63 billion yen, an increase of 13.5% from prior year. Basic earnings per share was 87.37 yen compa...
Full Year 2025 Eisai Co Ltd Earnings Presentation Transcript
Full Year 2025 Eisai Co Ltd Earnings Presentation Transcript
Merck (MRK) and Eisai Conclude Keytruda-Lenvima Trial for Liver Cancer
Merck (MRK) and Eisai Conclude Keytruda-Lenvima Trial for Liver Cancer